Evolent Health Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Evolent Health in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Evolent Health stock.
View analyst ratings for Evolent Health or view top-rated stocks.

Wall Street analysts have given Evolent Health a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Evolent Health wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Evolent Health is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Evolent Health.

Evolent Health, Inc. (NYSE:EVH) posted its quarterly earnings results on Wednesday, August, 4th. The technology company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.05. The technology company earned $222.06 million during the quarter, compared to analysts' expectations of $216.97 million. Evolent Health had a negative trailing twelve-month return on equity of 3.38% and a negative net margin of 7.28%.
View Evolent Health's earnings history.

Evolent Health's stock was trading at $6.92 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, EVH shares have increased by 282.2% and is now trading at $26.45.
View which stocks have been most impacted by COVID-19.

Evolent Health issued an update on its third quarter 2021 earnings guidance on Wednesday, September, 1st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $215 million-$230 million, compared to the consensus revenue estimate of $217.74 million.

5 Wall Street analysts have issued 12-month target prices for Evolent Health's shares. Their forecasts range from $25.00 to $35.00. On average, they anticipate Evolent Health's share price to reach $29.25 in the next year. This suggests a possible upside of 10.6% from the stock's current price.
View analysts' price targets for Evolent Health or view top-rated stocks among Wall Street analysts.

12 employees have rated Evolent Health CEO Seth Blackley on Glassdoor.com. Seth Blackley has an approval rating of 100% among Evolent Health's employees. This puts Seth Blackley in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Evolent Health include R1 RCM (RCM), Terminix Global (TMX), Premier (PINC), ManTech International (MANT), Franklin Covey (FC), PHI Group (PHIL), Jupai (JP), Taylor Consulting (TAYO) and Rainmaker Systems (VCTL).
View all of EVH's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Evolent Health investors own include CA (CA), BlackRock (BLK), Universal Insurance (UVE), Endologix (ELGX), Advanced Micro Devices (AMD), Energy Transfer (ET), Chipotle Mexican Grill (CMG), Ford Motor (F), Cisco Systems (CSCO) and Heron Therapeutics (HRTX).

(EVH) raised $150 million in an initial public offering (IPO) on Friday, June 5th 2015. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and Goldman Sachs acted as the underwriters for the IPO and Wells Fargo Securities, William Blair, SunTrust Robinson Humphrey and Leerink Partners were co-managers.

Evolent Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "EVH."

Evolent Health's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.52%), JPMorgan Chase & Co. (7.19%), BlackRock Inc. (6.65%), Credit Suisse AG (4.58%), Bellevue Group AG (4.19%) and Dimensional Fund Advisors LP (3.88%). Company insiders that own Evolent Health stock include Cheryl Scott, Frank J Williams, Frank J Williams, Jonathan Weinberg, Seth Blackley, Simon Maisey and Steve Tutewohl.
View institutional ownership trends for Evolent Health.

EVH stock was sold by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., JPMorgan Chase & Co., Fuller & Thaler Asset Management Inc., Kennedy Capital Management Inc., Invesco Ltd., Credit Suisse AG, BlackRock Inc., and Nuveen Asset Management LLC. Company insiders that have sold Evolent Health company stock in the last year include Cheryl Scott, Frank J Williams, Jonathan Weinberg, Simon Maisey, and Steve Tutewohl.
View insider buying and selling activity for Evolent Health or view top insider-selling stocks.

EVH stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, M&G Investment Management Ltd., Summit Creek Advisors LLC, Formula Growth Ltd., Renaissance Technologies LLC, Millennium Management LLC, Bridgewater Associates LP, and Northern Trust Corp.
View insider buying and selling activity for Evolent Health or or view top insider-buying stocks.

Shares of EVH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EVH stock can currently be purchased for approximately $26.45.

Evolent Health has a market capitalization of $2.31 billion and generates $1.02 billion in revenue each year. The technology company earns $-334,250,000.00 in net income (profit) each year or ($0.38) on an earnings per share basis.

Evolent Health employs 2,900 workers across the globe.

The official website for Evolent Health is www.evolenthealth.com.

Evolent Health is headquartered at 800 NORTH GLEBE RD SUITE 500, ARLINGTON VA, 22203.

Evolent Health's mailing address is 800 NORTH GLEBE RD SUITE 500, ARLINGTON VA, 22203. The technology company can be reached via phone at (571) 389-6000 or via email at [email protected]